Melody Cobleigh to Receptors, Estrogen
This is a "connection" page, showing publications Melody Cobleigh has written about Receptors, Estrogen.
Connection Strength
0.327
-
Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec; 28 Suppl 1:S39-47.
Score: 0.090
-
The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J. 2006 Jul-Aug; 12(4):360-2.
Score: 0.067
-
Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8623-31.
Score: 0.064
-
Hormone replacement therapy and high S phase in breast cancer. JAMA. 1999 Apr 28; 281(16):1528-30.
Score: 0.041
-
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res. 2013 Mar 01; 19(5):1281-9.
Score: 0.026
-
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
Score: 0.015
-
Predictors of lymph node metastasis in T1 breast carcinoma, stratified by patient age. Breast J. 2002 Nov-Dec; 8(6):349-55.
Score: 0.013
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.011